Table 4.
Factors associated with developing HCC at end of treatment
| Characteristics | Developing HCC | Non developing HCC | p |
|---|---|---|---|
| Platelets count (×104/µl) | 13.1 (4.0–20.1) | 16.1 (3.8–43.4) | 0.005 |
| AST (U/L) | 29 (16–81) | 24 (10–99) | 0.009 |
| ALT (U/L) | 23 (8–51) | 17 (4–106) | 0.306 |
| Total bilirubin (mg/dl) | 0.7 (0.4–1.6) | 0.7 (0.1–3.0) | 0.343 |
| Albumin (g/dl) | 3.8 (2.7–4.6) | 4.2 (2.7–5.3) | <0.001 |
| M2BPGi | 2.8 (1.0–9.2) | 1.1 (0.2–11.8) | <0.001 |
| AFP (ng/ml) | 4.6 (2.3–10.7) | 3.1 (0.9–27.1) | 0.008 |
| Serum zinc (µg/dl) | 56 (42–90) | 68 (42–142) | <0.001 |
Continuous variables expressed as median (range). AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; M2BPGi, Mac-2 binding protein glycosylation isomer.